MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Mavacoxib

CAS No. : 170569-88-7

MCE 国际站：Mavacoxib

产品活性：Mavacoxib 是一种选择性的口服长效环氧合酶 2 (COX-2) 抑制剂，是一种长效的非甾体类抗炎剂 (NSAID)，用于研究犬退化性关节病相关的疼痛和炎症。

研究领域：Immunology/Inflammation

作用靶点：COX

In Vitro: Mavacoxib (0-200 μM; 72 hours; CSKOS, U2OS, REM, K9TCC and T24 cells) treatment reduces cell viability in a dose-dependent manner. However, sensitivity to Mavacoxib varied between the cell lines, with IC₅₀ values ranging from 34.5 μM to 157.7 μM. The IC₅₀ values of U2OS, KTOSA5, CSKOS, REM, LILY, K9TCC, K9TCC-AXA, K9TCC-In, K9TCC-Sh, T24, 5637 and HT-1376 cells are 52.6 μM, 89.8 μM, 106.3 μM, 66.6 μM, 97.5 μM, 54.9 μM, 34.5 μM, 78.7 μM, 50.7 μM, 63.4 μM, 72.5 μM and 157.7 μM, respectively.
Mavacoxib (0-200 μM; 48 hours; KTOSA5, REM, LILY, K9TCC, U2OS, and T24 cells) treatment can induce caspase-dependent apoptosis in a number of cell lines.
Mavacoxib (0-75 μM; 24 hours; CSKOS, U2OS, REM, K9TCC and T24 cells) treatment down-regulates the expression of p-Akt in CSKOS cells in in a dose-dependent manner, as is total Akt in U2OS cells. In REM cells, both p-ERK and p-Akt are increased in expression with increasing doses of Mavacoxib, and in K9TCC cells p-ERK expression is also increased with Mavacoxib treatment.

In Vivo: Osteoarthritic dogs enrolled in the studies are randomized to receive treatment with Mavacoxib and daily placebo for carprofen or placebo for Mavacoxib and daily carprofen at a nominal dose of 4 mg/kg BW. Mavacoxib is administered in both studies with a 2-week interval between the first and second doses but with monthly dosing thereafter. The nominal Mavacoxib doses in Studies 1 and 2 are 4 and 2 mg/kg BW, respectively. Seven Mavacoxib doses are administered in Study 1, but only five doses in Study 2. In Study 1, Mavacoxib is administered without regard to the timing of meals, but in Study 2, all of the Mavacoxib doses are administered with food.

相关产品：Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Anti-Aging Compound Library  |  Pyroptosis Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Colorectal Cancer Compound Library   |  Antidepressant Compound Library  |  Protein-protein Interaction Inhibitor Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Heterocyclic Compound Library  |  Highly Selective Inhibitors Library  |  Meloxicam-d₃-1  |  4-Methylamino antipyrine hydrochloride  |  Vedaprofen-d₃  |  Pelubiprofen-¹³C,d₃  |  N-tert-Butyl-α-phenylnitrone-d₁₄  |  Tepoxalin  |  Ampyrone  |  Pectolinarigenin  |  Ermanin  |  Aceclofenac-d₄  |  SC-58125  |  Salicylic acid-¹³C₆  |  (±)-Naproxen-d₃-1  |  Dehydroevodiamine hydrochloride  |  Aspirin-d₄  |  Asaraldehyde  |  Broussonin E  |  (-)-Epicatechin  |  COX-2/15-LOX-IN-1  |  20(S)-Ginsenoside Rg3  |  Ginsenoside Rd  |  Salicylic acid-d₆  |  TFAP  |  Hydrangenol  |  Alminoprofen  |  Acetaminophen-d₃  |  FPL 62064  |  Crocin II  |  AG-024322  |  Ketoprofen-¹³C,d₃

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-119447

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。